Literature DB >> 17615261

Involvement of visinin-like protein-1 (VSNL-1) in regulating proliferative and invasive properties of neuroblastoma.

Yi Xie1, Hiuman Chan, Jianqing Fan, Yongxiong Chen, Joseph Young, Wen Li, Xiaoping Miao, Zhengwei Yuan, Huanmin Wang, Paul K H Tam, Yi Ren.   

Abstract

Tumor growth and metastasis require that tumor cells must have either the potential to shift genetically or epigenetically between proliferative and invasive phenotypes or both phenotypes simultaneously. In the present study, we demonstrated that neuroblastoma growth and invasion were distinct processes that were carried out by proliferative and invasive phenotypes of tumor cells, respectively. Two subpopulations from human neuroblastoma cell line were isolated: highly invasive (HI) cells and low-invasive (LI) cells. HI and LI cells had different proliferative rate and metastatic ability in vitro and in vivo. In addition, they had distinct activated signal pathways and sensitivities to chemotherapy drugs. Affymetrix microarray and quantitative reverse transcriptase-polymerase chain reaction revealed that visinin-like protein-1 (VSNL-1) mRNA in HI cells was significantly higher than that in LI cells. We also observed that VSNL-1 was over-expressed in tumor specimens from patients with distant organ metastases compared with those without metastases. Furthermore, the invasive and proliferative phenotypes of neuroblastoma cells could be exchanged by regulation of VSNL-1 expression in vitro and in vivo. Up-regulation of VSNL-1 potentiated the anoikis-resistant ability of neuroblastoma cell. The expression of anoikis inhibitor TrkB, intracellular adhesion molecule 1, major histocompatibility complex class I, CD44 and CD44v6 was associated with VSNL-1 level. These results suggested that distinct roles of proliferative and invasive phenotypes contributed to neuroblastoma progression and strongly demonstrated that VSNL-1 played a very important role in neuroblastoma metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17615261     DOI: 10.1093/carcin/bgm147

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  RANDOM LASSO.

Authors:  Sijian Wang; Bin Nan; Saharon Rosset; Ji Zhu
Journal:  Ann Appl Stat       Date:  2011-03-01       Impact factor: 2.083

Review 2.  Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+ -sensor proteins.

Authors:  Karl-Heinz Braunewell; Andres J Klein-Szanto; Andres J Klein Szanto
Journal:  Cell Tissue Res       Date:  2008-11-07       Impact factor: 5.249

3.  Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

Authors:  Purificacion Estevez-Garcia; Fernando Rivera; Sonia Molina-Pinelo; Marta Benavent; Javier Gómez; Maria Luisa Limón; Maria Dolores Pastor; Julia Martinez-Perez; Luis Paz-Ares; Amancio Carnero; Rocio Garcia-Carbonero
Journal:  Oncotarget       Date:  2015-03-20

4.  VSNL1 Promotes Gastric Cancer Cell Proliferation and Migration by Regulating P2X3/P2Y2 Receptors and Is a Clinical Indicator of Poor Prognosis in Gastric Cancer Patients.

Authors:  Qiao-Qiong Dai; Yuan-Yu Wang; Yu-Peng Jiang; Li Li; Hui-Ju Wang
Journal:  Gastroenterol Res Pract       Date:  2020-12-09       Impact factor: 2.260

5.  Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.

Authors:  Astrid Rohrbeck; Jürgen Borlak
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

6.  Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Authors:  Ryan R Gordon; Mengchu Wu; Chung-Ying Huang; William P Harris; Hong Gee Sim; Jared M Lucas; Ilsa Coleman; Celestia S Higano; Roman Gulati; Lawrence D True; Robert Vessella; Paul H Lange; Mark Garzotto; Tomasz M Beer; Peter S Nelson
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.